Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Accounts Payable & Accrued Expense : HK$449.7 Mil (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Sichuan Kelun-Biotech Biopharmaceutical Co Accounts Payable & Accrued Expense?

Sichuan Kelun-Biotech Biopharmaceutical Co's quarterly accounts payable & accrued expense declined from Dec. 2022 (HK$406.2 Mil) to Jun. 2023 (HK$343.5 Mil) but then increased from Jun. 2023 (HK$343.5 Mil) to Dec. 2023 (HK$449.7 Mil).

Sichuan Kelun-Biotech Biopharmaceutical Co's annual accounts payable & accrued expense declined from Dec. 2021 (HK$443.8 Mil) to Dec. 2022 (HK$406.2 Mil) but then increased from Dec. 2022 (HK$406.2 Mil) to Dec. 2023 (HK$449.7 Mil).

Sichuan Kelun-Biotech Biopharmaceutical Co Accounts Payable & Accrued Expense Historical Data

The historical data trend for Sichuan Kelun-Biotech Biopharmaceutical Co's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sichuan Kelun-Biotech Biopharmaceutical Co Accounts Payable & Accrued Expense Chart

Sichuan Kelun-Biotech Biopharmaceutical Co Annual Data

Trend

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

443.80

406.16

449.69

Sichuan Kelun-Biotech Biopharmaceutical Co Quarterly Data
	Sep21	Dec21	Jun22	Sep22	Dec22	Jun23	Dec23
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial			-	365.62	406.16	343.48	449.69

Sichuan Kelun-Biotech Biopharmaceutical Co Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sichuan Kelun-Biotech Biopharmaceutical Co Ltd (HKSE:06990) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 666 Xinhua Avenue, Chengdu Cross-Strait Science and Technology Industry Development Park, Wenjiang, Sichuan, Chengdu, CHN

Website

http://www.kelun-biotech.com

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is an innovative biopharmaceutical company committed to the R&D, manufacturing and commercialization of novel drugs to address medical needs in China and globally. It is one of the first movers in the development of antibody-drug conjugates (ADCs), with over a decade of accumulated experience in ADC development. The company takes a systematic, indication-oriented approach to target the world's prevalent or hard-to-treat cancers, and other diseases and conditions affecting a large and underserved population.

Executives

Liu Gexin	2201 Interest of corporation controlled by you
Si Chuan Ke Lun Yao Ye Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you
Cheng Du Ke Lun Jing Chuan Ke Ji You Xian Gong Si	2201 Interest of corporation controlled by you
Wellington Management Group Llp	2102 Investment manager
Merck & Co., Inc.	2201 Interest of corporation controlled by you
Merck Sharp & Dohme Llc	2101 Beneficial owner
Ke Lun Guo Ji Fa Zhan You Xian Gong Si	2101 Beneficial owner
Li Jun	2201 Interest of corporation controlled by you
Zhou Quan	2201 Interest of corporation controlled by you
Idg Breyer Capital Fund Gp Associates L.p.	2201 Interest of corporation controlled by you
Idg Breyer Capital Fund Gp Associates Ltd.	2201 Interest of corporation controlled by you
Idg Breyer Capital Fund L.p.	2201 Interest of corporation controlled by you
Victory Rhythm Limited	2201 Interest of corporation controlled by you
Wealthy Linkage Limited	2101 Beneficial owner
Ho Chi Sing	2201 Interest of corporation controlled by you

Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Headlines

No Headlines